Skip to Content

Vertex got its start ­making a hepatitis C drug, but it has more recently homed in on medicine that treats symptoms of cystic fibrosis, a genetic disease that afflicts 75,000 people worldwide. Its two bestselling drugs, Orkambi and Kalydeco, account for 87% of its $2.6 billion in revenue. And in February, Vertex received approval of a third CF drug, Symdeko, which earned $186 million in its first quarter on the market—more than twice what analysts expected. The success of the drugs has helped Vertex more than double its revenue in three years.

Company Information

Overall Score4.6
Sector
Health Care
Industry
Biotechnology
CEO
Jeffrey M. Leiden
Websitehttp://www.vrtx.com
Employees2,300
HQ Location
Boston
Revenues ($M) (Past 12 Months)$2,623
Profits ($M) (Past 12 Months)$415
Market Value as of Oct. 10, 2018 ($M)$45,088